Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01080820 | A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers | PHASE1 | COMPLETED | 36 | — | — | Jun 1, 2010 | Dec 1, 2010 | Jul 4, 2011 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Placebo + Viread | PLACEBO_COMPARATOR | - |
| Viread | ACTIVE_COMPARATOR | - |
| CMX157 + Viread | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CMX157 | DRUG | One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose. |
| Placebo | DRUG | One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose. |
| Viread | DRUG | One single oral dose of 300mg Viread. |
Inclusion Criteria: 1\. Males or females of non-childbearing potential, 18 to 55 years of age. Males must be able and willing to use adequate contraceptive methods throughout the study. Exclusion Criteria: 1. Currently nursing females, pregnant females, or females of child-bearing potential. 2. H...